Astria Therapeutics, Inc.
ATXS
$7.49
-$0.04-0.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.40% | -32.35% | -29.32% | -82.75% | -90.23% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.92% | 20.41% | 24.00% | 64.00% | 83.33% |
| Change in Net Operating Assets | -311.42% | 708.33% | 288.27% | -431.40% | 1,510.64% |
| Cash from Operations | -43.57% | -29.41% | -18.65% | -92.52% | -79.17% |
| Capital Expenditure | -87.69% | -1,525.00% | -1,200.00% | -752.50% | -245.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 145.74% | 80.27% | -241.80% | -9,945.49% | -5,080.41% |
| Cash from Investing | 145.35% | 80.10% | -242.07% | -10,172.14% | -5,210.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.35% | -93.31% | 77.83% | 102.94% | 58.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.35% | -93.31% | 77.83% | 102.94% | 58.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.35% | -288.89% | -174.75% | -152.92% | -144.94% |